Skip to content

Clinical trial on the safety and efficacy of transfusing common RhD-positive blood in Asian-type DEL patients

Multicenter, single-arm clinical trial on the safety and efficacy of transfusing common RhD-positive blood in Asian-type DEL patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124838
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Red blood cell transfusion

Interventions

Asian-type DEL patients:Transfusion of ABO-identical, RhD-positive blood that is cross-match compatible.

Sponsors

Guabgzhou First People‘s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult male Asian-type DEL blood group patients aged 18–80 years, or non-reproductive female Asian-type DEL blood group patients aged 49–80 years. 2. Patients who are clinically indicated for red blood cell transfusion in accordance with the Medical, Surgical, and Trauma Transfusion Guidelines of the "Technical Specifications for Clinical Blood Transfusion," taking into account the patient's severity of anemia, cardiopulmonary compensation, metabolic rate, age, and other factors; 3. Voluntary signing of the informed consent form for the clinical trial transfusion therapy before the trial. The patient and/or their legal representative must have the capacity to fully understand the trial content, procedures, and possible adverse reactions, and be able to comply with the protocol-specified visits and examinations;

Exclusion criteria

Exclusion criteria: 1. Patients with a history of severe transfusion adverse reactions. 2. Patients requiring emergency blood transfusion for acute blood loss due to trauma or other causes. 3. Patients with impaired consciousness or severe mental illness. 4. Other patients deemed by the investigator to be unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Anti-D alloimmunization rate;

Secondary

MeasureTime frame
Rate of autoantibody mimicking anti-D;Hemoglobin concentration and hematocrit testing;

Countries

China

Contacts

Public ContactYongshui Fu

Guabgzhou First People‘s Hospital

fuyongshui@sina.com+86 20 83586171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026